Cardiac warning for Parkinson's medications

Combined treatment with apomorphine and domperidone in patients with Parkinson's disease requires cardiac monitoring to reduce the risk of serious arrhythmias, the MHRA has advised.

Domperidone is usually started at least two days before apomorphine to control the side-effects of nausea and vomiting. | SCIENCE PHOTO LIBRARY
Domperidone is usually started at least two days before apomorphine to control the side-effects of nausea and vomiting. | SCIENCE PHOTO LIBRARY

A European review published in 2014 found that domperidone (eg, Motilium) is associated with a small increased risk of QT prolongation, ventricular arrhythmia and cardiac death. As a result, the drug's licensed indication was restricted to relief of nausea and vomiting.

At high doses, apomorphine (APO-go) can also increase the risk of QT prolongation.

Further information
MHRA Drug Safety Update

Before starting concomitant treatment with apomorphine and domperidone, the MHRA now advises that healthcare professionals carefully consider whether the clinical need outweighs the small increased likelihood of cardiac side-effects. It is important to discuss the benefits and risks with patients and their carers.

The QT interval must be checked before starting domperidone, during the apomorphine initiation phase and as clinically indicated thereafter (eg, if a QT-prolonging or interacting drug is started or if cardiac symptoms are reported).

During treatment, patients should be advised to immediately report any palpitations or syncopal symptoms and to inform their doctor of any changes that could increase their risk of arrhythmia, such as symptoms of cardiac or hepatic disorders, conditions that could cause electrolyte disturbances (eg, gastroenteritis or starting a diuretic) or starting another medication.

Treatment must be regularly reviewed to ensure patients take the lowest effective domperidone dose for the shortest duration.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Cautious welcome for new Parkinson's drug safinamide

Cautious welcome for new Parkinson's drug safinamide

Xadago (safinamide) is the first new drug for Parkinson's...

MHRA limits use of domperidone

MHRA limits use of domperidone

The MHRA has issued new advice for domperidone which...

Multidisciplinary management of Parkinson's disease

Multidisciplinary management of Parkinson's disease

The GP's role is to co-ordinate holistic care, writes...

Domperidone cardiac warning

Domperidone cardiac warning

The MHRA has issued guidance regarding the risk of...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases